TRS
Back to Database

Cagrilintide

Phase 3 Clinical Trials

Also known as: NN9838

GLP-1 / Weight LossSubcutaneous

A long-acting amylin analog being developed in combination with semaglutide (CagriSema) for obesity and type 2 diabetes treatment.

Molecular Weight~3950 Da
Half-Life (t½)~7 days
SequenceLong-acting amylin analog

Mechanism of Action

Activates amylin receptors in the brain to promote satiety, slow gastric emptying, and suppress glucagon secretion. Complementary pathway to GLP-1.

Dosing Protocol

Titrated from 0.25mg weekly up to 2.4mg weekly. Often combined with semaglutide.

Open peptide calculator

Reconstitution

Research-grade: 10mg vial + 2mL BAC water.

Storage

Refrigerate 2-8°C.

Side Effects

  • ●Nausea
  • ●Injection site reactions
  • ●Diarrhea

Key Research Findings

  • ●CagriSema combination: ~15.6% weight loss at 32 weeks
  • ●Additive effects with GLP-1 agonists on appetite suppression
  • ●Improved postprandial glucose control

Latest Verified Lab Report

No lab reports available for Cagrilintide yet.

Community-funded testing results will appear here.

Vendor Trust Leaderboard

For Cagrilintide

Trust leaderboard coming soon.

Vendor rankings based on verified lab test results.

Active Deals

APR Health Solutions
15% OFF
A

15% off with code at checkout.

TheResearchStop
Shop Vendor
Ameano Peptides
10% OFF
A

10% off with code at checkout.

theresearchstop
Shop Vendor
Puratek Peptides
10% OFF
Puratek Peptides

10% off — discount applied automatically via referral link.

Shop Vendor
Mile High Compounds
10% OFF
M

10% off with code at checkout.

theresearchstop
Shop Vendor
Advertisement

Sponsored Ad Space

Advertise with us

Research Use Only

This information is provided for educational and research purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before using any research compounds.